BRISTOL-MYERS SQUIBB COMPANY Impairment of Long-Lived Assets to be Disposed of
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Impairment of Long-Lived Assets to be Disposed of of $834.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY impairment of long-lived assets to be disposed of for the quarter ending 2026-06-30 was $422.00M, a 34.82% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY impairment of long-lived assets to be disposed of for the quarter ending 2026-03-31 was $412.00M, a 8140.00% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY impairment of long-lived assets to be disposed of for the quarter ending 2025-12-31 was $584.00M, a 70.10% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY impairment of long-lived assets to be disposed of for the quarter ending 2025-09-30 was $196.00M, a 41.01% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY impairment of long-lived assets to be disposed of for fiscal 2025 was $1.10B, a 62.94% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY impairment of long-lived assets to be disposed of for fiscal 2024 was $2.96B, a 1061.96% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY impairment of long-lived assets to be disposed of for fiscal 2023 was $255.00M, a 42.46% increase from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY impairment of long-lived assets to be disposed of for fiscal 2022 was $179.00M, a 85.17% decline from fiscal 2021.
| Period end | Impairment of Long-Lived Assets to be Disposed of 3 month | Impairment of Long-Lived Assets to be Disposed of 6 month | Impairment of Long-Lived Assets to be Disposed of 9 month | Impairment of Long-Lived Assets to be Disposed of 12 month | Impairment of Long-Lived Assets to be Disposed of 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $422.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $834.00M 10-Q · filed 2026-07-30 | $1.42B derived: sum of 3 quarters · filed 2026-07-30 | $1.61B derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | $412.00M 10-Q · filed 2026-04-30 | $996.00M derived: sum of 2 quarters · filed 2026-04-30 | $1.19B derived: sum of 3 quarters · filed 2026-04-30 | $1.50B derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $584.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $780.00M derived: sum of 2 quarters · filed 2026-02-11 | $1.09B derived: sum of 3 quarters · filed 2026-07-30 | $1.10B 10-K · filed 2026-02-11 | |
| 2025-09-30 | $196.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $509.00M derived: sum of 2 quarters · filed 2026-07-30 | $514.00M 10-Q · filed 2025-10-30 | $2.47B derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $313.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $318.00M 10-Q · filed 2026-07-30 | $2.27B derived: sum of 3 quarters · filed 2026-07-30 | $2.41B derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | $5.00M 10-Q · filed 2026-04-30 | $1.96B derived: sum of 2 quarters · filed 2026-04-30 | $2.10B derived: sum of 3 quarters · filed 2026-04-30 | $2.97B derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $1.95B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $2.09B derived: sum of 2 quarters · filed 2026-02-11 | $2.96B derived: sum of 3 quarters · filed 2026-02-11 | $2.96B 10-K · filed 2026-02-11 | |
| 2024-09-30 | $139.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.01B derived: sum of 2 quarters · filed 2025-10-30 | $1.01B 10-Q · filed 2025-10-30 | $1.04B derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-06-30 | $870.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $871.00M 10-Q · filed 2025-07-31 | $900.00M derived: sum of 3 quarters · filed 2026-02-11 | $1.06B derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-03-31 | $1.00M 10-Q · filed 2024-04-25 | $30.00M derived: sum of 2 quarters · filed 2026-02-11 | $189.00M derived: sum of 3 quarters · filed 2026-02-11 | $236.00M derived: sum of 4 quarters · filed 2026-02-11 | |
| 2023-12-31 | $29.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $188.00M derived: sum of 2 quarters · filed 2026-02-11 | $235.00M derived: sum of 3 quarters · filed 2026-02-11 | $255.00M 10-K · filed 2026-02-11 | |
| 2023-09-30 | $159.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $206.00M derived: sum of 2 quarters · filed 2024-10-31 | $226.00M 10-Q · filed 2024-10-31 | $261.00M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-06-30 | $47.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-26 | $67.00M 10-Q · filed 2024-07-26 | $102.00M derived: sum of 3 quarters · filed 2025-02-12 | $163.00M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-03-31 | $20.00M 10-Q · filed 2024-04-25 | $55.00M derived: sum of 2 quarters · filed 2025-02-12 | $116.00M derived: sum of 3 quarters · filed 2025-02-12 | $158.00M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2022-12-31 | $35.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $96.00M derived: sum of 2 quarters · filed 2025-02-12 | $138.00M derived: sum of 3 quarters · filed 2025-02-12 | $179.00M 10-K · filed 2025-02-12 | |
| 2022-09-30 | $61.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $103.00M derived: sum of 2 quarters · filed 2023-10-26 | $144.00M 10-Q · filed 2023-10-26 | $159.00M derived: sum of 4 quarters · filed 2024-02-13 | |
| 2022-06-30 | $42.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-27 | $83.00M 10-Q · filed 2023-07-27 | $98.00M derived: sum of 3 quarters · filed 2024-02-13 | $711.00M derived: sum of 4 quarters · filed 2024-02-13 | |
| 2022-03-31 | $41.00M 10-Q · filed 2023-04-27 | $56.00M derived: sum of 2 quarters · filed 2024-02-13 | $669.00M derived: sum of 3 quarters · filed 2024-02-13 | $909.00M derived: sum of 4 quarters · filed 2024-02-13 | |
| 2021-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $628.00M derived: sum of 2 quarters · filed 2024-02-13 | $868.00M derived: sum of 3 quarters · filed 2024-02-13 | $1.21B 10-K · filed 2024-02-13 | |
| 2021-09-30 | $613.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-26 | $853.00M derived: sum of 2 quarters · filed 2022-10-26 | $1.19B 10-Q · filed 2022-10-26 | $2.26B derived: sum of 4 quarters · filed 2023-02-14 | |
| 2021-06-30 | $240.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $579.00M 10-Q · filed 2022-07-27 | $1.65B derived: sum of 3 quarters · filed 2023-02-14 | $1.67B derived: sum of 4 quarters · filed 2023-02-14 | |
| 2021-03-31 | $339.00M 10-Q · filed 2022-04-29 | $1.41B derived: sum of 2 quarters · filed 2023-02-14 | $1.43B derived: sum of 3 quarters · filed 2023-02-14 | $1.49B derived: sum of 4 quarters · filed 2023-02-14 | |
| 2020-12-31 | $1.07B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $1.09B derived: sum of 2 quarters · filed 2023-02-14 | $1.15B derived: sum of 3 quarters · filed 2023-02-14 | $1.20B 10-K · filed 2023-02-14 | |
| 2020-09-30 | $15.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $78.00M derived: sum of 2 quarters · filed 2021-10-27 | $131.00M 10-Q · filed 2021-10-27 | $147.00M derived: sum of 4 quarters · filed 2022-02-09 | |
| 2020-06-30 | $63.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | $116.00M 10-Q · filed 2021-07-28 | $132.00M derived: sum of 3 quarters · filed 2022-02-09 | $141.00M derived: sum of 4 quarters · filed 2022-02-09 | |
| 2020-03-31 | $53.00M 10-Q · filed 2021-04-29 | $69.00M derived: sum of 2 quarters · filed 2022-02-09 | $78.00M derived: sum of 3 quarters · filed 2022-02-09 | $207.00M derived: sum of 4 quarters · filed 2022-02-09 | |
| 2019-12-31 | $16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $25.00M derived: sum of 2 quarters · filed 2022-02-09 | $154.00M derived: sum of 3 quarters · filed 2022-02-09 | $199.00M 10-K · filed 2022-02-09 | |
| 2019-09-30 | $9.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $138.00M derived: sum of 2 quarters · filed 2020-11-05 | $183.00M 10-Q · filed 2020-11-05 | $199.00M derived: sum of 4 quarters · filed 2021-02-10 | |
| 2019-06-30 | $129.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $174.00M 10-Q · filed 2020-08-06 | $190.00M derived: sum of 3 quarters · filed 2021-02-10 | $196.00M derived: sum of 4 quarters · filed 2021-02-10 | |
| 2019-03-31 | $45.00M 10-Q · filed 2020-05-07 | $61.00M derived: sum of 2 quarters · filed 2021-02-10 | $67.00M derived: sum of 3 quarters · filed 2021-02-10 | $91.00M derived: sum of 4 quarters · filed 2021-02-10 | |
| 2018-12-31 | $16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $22.00M derived: sum of 2 quarters · filed 2021-02-10 | $46.00M derived: sum of 3 quarters · filed 2021-02-10 | $126.00M 10-K · filed 2021-02-10 | |
| 2018-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $30.00M derived: sum of 2 quarters · filed 2019-10-31 | $110.00M 10-Q · filed 2019-10-31 | $214.00M derived: sum of 4 quarters · filed 2020-02-24 | |
| 2018-06-30 | $24.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-25 | $104.00M 10-Q · filed 2019-07-25 | $208.00M derived: sum of 3 quarters · filed 2020-02-24 | $212.00M derived: sum of 4 quarters · filed 2020-02-24 | |
| 2018-03-31 | $80.00M 10-Q · filed 2019-04-25 | $184.00M derived: sum of 2 quarters · filed 2020-02-24 | $188.00M derived: sum of 3 quarters · filed 2020-02-24 | $329.00M derived: sum of 4 quarters · filed 2020-02-24 | |
| 2017-12-31 | $104.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $108.00M derived: sum of 2 quarters · filed 2020-02-24 | $249.00M derived: sum of 3 quarters · filed 2020-02-24 | $327.00M 10-K · filed 2020-02-24 | $332.00M 10-K · filed 2018-02-13 |
| 2017-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $145.00M derived: sum of 2 quarters · filed 2018-10-25 | $223.00M 10-Q · filed 2018-10-25 | $211.00M derived: sum of 4 quarters · filed 2019-02-25 | |
| 2017-06-30 | $141.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $219.00M 10-Q · filed 2018-07-26 | $207.00M derived: sum of 3 quarters · filed 2019-02-25 | $214.00M derived: sum of 4 quarters · filed 2019-02-25 | |
| 2017-03-31 | $78.00M 10-Q · filed 2018-04-26 | $66.00M derived: sum of 2 quarters · filed 2019-02-25 | $73.00M derived: sum of 3 quarters · filed 2019-02-25 | $122.00M derived: sum of 4 quarters · filed 2019-02-25 | |
| 2016-12-31 | -$12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | -$5.00M derived: sum of 2 quarters · filed 2019-02-25 | $44.00M derived: sum of 3 quarters · filed 2019-02-25 | $63.00M 10-K · filed 2019-02-25 | $108.00M 10-K · filed 2017-02-21 |
| 2016-09-30 | $7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | $56.00M derived: sum of 2 quarters · filed 2017-10-26 | $75.00M 10-Q · filed 2017-10-26 | ||
| 2016-06-30 | $49.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | $68.00M 10-Q · filed 2017-07-27 | |||
| 2016-03-31 | $19.00M 10-Q · filed 2017-04-27 | ||||
| 2015-12-31 | $192.00M 10-K · filed 2018-02-13 | ||||
| 2014-12-31 | $401.00M 10-K · filed 2017-02-21 | ||||
| 2013-12-31 | $40.00M 10-K · filed 2016-02-12 | ||||
| 2012-12-31 | $2.18B 10-K · filed 2015-02-13 | ||||
| 2011-12-31 | $28.00M 10-K · filed 2014-02-14 | ||||
| 2010-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $13.00M derived: sum of 2 quarters · filed 2013-02-15 | $28.00M derived: sum of 3 quarters · filed 2013-02-15 | $228.00M 10-K · filed 2013-02-15 | |
| 2010-09-30 | $10.00M 10-Q · filed 2011-10-27 | $25.00M derived: sum of 2 quarters · filed 2011-10-27 | $225.00M 10-Q · filed 2011-10-27 | ||
| 2010-06-30 | $15.00M 10-Q · filed 2011-07-28 | $215.00M 10-Q · filed 2011-10-27 | |||
| 2010-03-31 | $200.00M 10-Q · filed 2011-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |